Rapport Therapeutics (RAPP) Change in Accured Expenses (2023 - 2026)

Rapport Therapeutics (RAPP) has 4 years of Change in Accured Expenses data on file, last reported at -$3.5 million in Q1 2026.

• Change in Accured Expenses for Q1 2026 came in at -$3.5 million, down 1154.68% year-over-year; the trailing twelve-month figure through Mar 2026 was $2.3 million (up 349.9% YoY), and the FY2025 annual result was $6.2 million, up 1561.99% from the prior year.
• Change in Accured Expenses eased to -$3.5 million in Q1 2026 per RAPP's latest filing, from $3.7 million in the prior quarter.
• Over five years, Change in Accured Expenses peaked at $3.7 million in Q4 2025 and troughed at -$3.5 million in Q1 2026.
• A 4-year average of $684363.6 and a median of $453000.0 in 2025 frame the typical range for Change in Accured Expenses.
• The sharpest annual moves came in 2025 and 2026: Change in Accured Expenses surged 433.33% in 2025, then plunged 1154.68% in 2026.
• A 4-year view of Change in Accured Expenses shows it stood at $3.4 million in 2023, then slumped by 74.89% to $848000.0 in 2024, then soared by 334.67% to $3.7 million in 2025, then plunged by 194.71% to -$3.5 million in 2026.
• Business Quant data shows RAPP's Change in Accured Expenses at -$3.5 million in Q1 2026, $3.7 million in Q4 2025, and $1.7 million in Q3 2025.